Routine officer appointment with no stock-moving implications. Monitor for potential transition to full-time employment or changes in engagement level, but no immediate trading catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 28 $1.56entry
- T+1 · 6mo ago −19.23%α −19.47% · $1.26
- T+5 · 6mo ago −44.36%α −44.31% · $0.8680
- T+20 · 5mo ago −74.64%α −71.50% · $0.3956
- T+60 · 3mo ago −91.19%α −92.92% · $0.1375
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BiomX Inc. appointed Roy Rousso as Chief Business Officer (and, per the consulting agreement, COO/CBO) effective July 1, 2026, via a consulting agreement with $11,900/month base compensation at a 70% engagement level, plus eligibility for an annual performance bonus of up to $71,400 and a 200,000-share equity grant vesting over three years. This is a routine officer appointment with no material financial data or strategic changes disclosed, and no departures were announced.
Key Facts
- Appointed Roy Rousso as Chief Business Officer effective July 1, 2026
- Consulting agreement: $11,900/month base fee (70% of full-time $17,000/month)
- Annual performance bonus up to 50% of base fee (up to $71,400 per annum at 70% engagement)
- Equity grant of 200,000 shares of common stock, vesting in 3 equal annual installments
- 12-month post-termination non-compete and non-solicitation covenants
- Part-time independent contractor arrangement; parties intend to transition to full-time salaried employment as business develops
Financial Impact
Annual cash compensation of approximately $142,800 in base fee plus up to $71,400 bonus potential at current engagement level; 200,000 share equity award with three-year vesting
Risk Factors
- Part-time engagement may limit bandwidth relative to a full-time COO/CBO
- Equity grant adds modest shareholder dilution (~200K shares vs $16M market cap)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-061772 |
| Document: ea0292479-8k_biomx.htm | 0001213900-26-061772 |
| Document: 0001213900-26-061772-index-headers.html | 0001213900-26-061772 |
| Document: 0001213900-26-061772-index.html | 0001213900-26-061772 |
| Document: 0001213900-26-061772.txt | 0001213900-26-061772 |
Track record
22 reports on PHGE
8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +62.36% at T+20 after the Jun 16, 2026 report. 8 of 12 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Neutral 4/10 Entry $0.3092 to $0.2915 ▼ −5.72% −5.30% vs SPY
- Oct 7, 20265w ago DEF 14A Bearish 6/10 Entry $0.3092 to $0.2915 ▲ +5.72% +5.30% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $0.1425 to $0.1421 ▼ −0.28% −1.33% vs SPY
- Aug 28, 202611w ago 8-K Neutral 4/10 Entry $0.1371 to $0.1430 ▲ +4.30% +4.99% vs SPY
- Aug 5, 202614w ago Press Release Bearish 5/10 Entry $0.1800 to $0.1598 ▲ +11.22% +11.06% vs SPY
- Jul 28, 202615w ago 8-K Bearish 8/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 28, 202615w ago Press Release Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 27, 202616w ago 424B5 Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 8, 202618w ago Press Release Neutral 4/10 Entry $0.2758 to $0.2800 ▲ +1.52% +0.68% vs SPY
- Jul 2, 202619w ago 8-K Bearish 6/10 Entry $0.3190 to $0.3020 ▲ +5.33% +6.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers